Open Label, Adaptive Design, Ascending, Multiple-Dose Study to Evaluate Safety and Efficacy of BMS-986004 in Adult Subjects With Primary Immune Thrombocytopenia (ITP)
Description
Brief Summary
The purpose of this study is to assess the safety and tolerability of BMS-986004 when
administered in subjects with ITP.
Phase
Phase 2 - takes the treatment one step further, assessing the activity of a particular therapy in a disease, often building upon leads from the Phase I trial. While patients are generally required to be previously untreated, participation in a Phase II trial doesn't usually preclude the patient from getting the standard treatment after they've received the investigational agent. At best they are allowed to get a new drug they wouldn't be able to get otherwise that may turn out to be better for their disease.Inclusion and Exclusion Criteria
- ≥18 years old, diagnosed with persistent or chronic ITP
- Secondary immune thrombocytopenia
- Drug induced thrombocytopenia
Sites
Please contact Gangothri Namasivayam to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI